Development of the INI-4001 and INI-2002 adjuvants within the context of a vaccine to prevent Lyme disease.

NIH RePORTER · NIH · N01 · $1,000,000 · view on reporter.nih.gov ↗

Abstract

Lyme disease, caused by the bite of Borrelia burgdorferi-infect Ixodes ticks, affects close to half a million Americans each year and can cause serious, long term, chronic health issues such as Lyme arthritis, Lyme encephalopathy, or skin disorders. No human vaccine is currently available and the contractor proposes to develop a novel subunit Lyme disease vaccine adjuvanted with a combination adjuvant composed of two synthetic TLR agonists (TLR4 and TLR7/8).

Key facts

NIH application ID
10667372
Project number
272201800048C-P00011-9999-1
Recipient
UNIVERSITY OF MONTANA
Principal Investigator
JAY EVANS
Activity code
N01
Funding institute
NIH
Fiscal year
2022
Award amount
$1,000,000
Award type
Project period
2018-09-30 → 2024-09-29